🇪🇺 UPC
UPC_CoA_646/2025
Court
Court of Appeal (Luxembourg)
Type of action
appeal
Patent
METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
Language
en
Claimant / applicant
- Amgen N.V.
- Amgen GmbH
- Amgen Inc.
- Amgen S.A.S.
- Amgen Europe B.V.
- Amgen B.V.
- Amgen S.R.L
Defendant / respondent
- Regeneron Pharmaceuticals Inc. and Sanofi Biotechnology SAS
- Sanofi Biotechnology SAS
- Regeneron Pharmaceuticals Inc.
- Sanofi Biotechnology SAS, Gentily
Track this case
Get an email when a new order or decision is published in UPC_CoA_646/2025.
Decisions and documents (1)
- 2026-03-24order on merits
- Appellants:
- Amgen B.V.; Amgen Europe B.V.; Amgen GmbH; Amgen Inc.; Amgen N.V.; Amgen S.A.S.; Amgen S.R.L
- Respondents:
- Regeneron Pharmaceuticals Inc.; Sanofi Biotechnology SAS
Appeal RoP220.1. Document: Final decision withdrawal in 646-2025.pdf. Case page: https://www.unifiedpatentcourt.org/en/node/182920
Judge: Rian Kalden • Panel: Ingeborg Simonsson, Rainer Friedrich, Cornelis Schüller, Patricia Rombach, Rian Kalden
Weekly digest
A weekly email summarising new published decisions across European patent courts.